BOSTON– Constant Therapy, an innovator of science-based, customized brain rehabilitation apps founded by Boston University Professor Swathi Kiran, has raised $2 million in Series A financing.
Golden Seeds led the round with participation from Kapor Capital, Launchpad Venture Group, Pond Capital and Community Health Network of Connecticut. The investment will enable the company to expand the scientific research, data, marketing and development behind its product, the company said in a statement.
The company was founded in 2013 by Kiran, who was head of the Aphasia Research Laboratory. While working with patients, Kiran noticed that people with cognitive, language, an
d speech disorders could benefit from a tool that combined technology with communication therapy. She teamed up with three notable technologists to develop mobile versions of proven speech therapy tasks and co-founded the company. They include: Dr. Veera Anantha, President, Mahendra Advani, Architect and Ehsan Dadgar, Mobile Development Lead.
Constant Therapy’s customized rehabilitation program, which enables continuous therapy anytime, any place, has earned accolades from national organizations in recent months including: the American Heart Association People’s Choice Award for Best Health Technology, AARP 2015 Consumer Choice Award for Health Innovation and Village Capital and Global Health & Social Innovation Capital Partners Award.
“Constant Therapy quite literally puts speech, language and cognitive therapy in your pocket,” said Keith Cooper, CEO and serial entrepreneur who joined the company last spring. “Developed by some of the world’s foremost experts in brain rehabilitation, it allows us to harness both data and science to optimize the effectiveness of treatment, customize it for each patient and then deliver it for individual use, or as an integral part of clinician-led therapy.”
Constant Therapy’s mobile solution is aimed at improving the cognitive and language skills of patients with stroke, brain injury, dementia, aphasia and learning disorders so they can perform better at everyday tasks. Patients are able to accelerate their recovery via the company’s NeuroPerformance Engine™, an advanced analytics engine, which analyzes patient performance and automatically customizes their therapy program for their specific needs. The company’s growing library of therapeutic tools today includes 65 science-based therapy categories and more than 60,000 exercises.
“We believe Constant Therapy can be a disruptive positive force in the $10 billion market for brain rehabilitation services,” said Kevin Ohashi, PhD, managing partner and co-founder of Pond Capital. “Unlike traditional paper-based therapies that rely on static and manually delivered exercises, its mobile exercises are dynamic, updated constantly and customized for each patient. Clinicians can use Constant Therapy with their patients in clinic and the patients can continue to work independently when they go home.”
Constant Therapy is the only company that partners with speech and language pathologists and other therapists by giving them access to the full version of the program for free to use with patients in their care. Some healthcare organizations that use Constant Therapy include Spaulding Rehabilitation Network, the Stroke Comeback Center and The MossRehab Aphasia Center.
Patients can use the program at home by purchasing a subscription to Constant Therapy for $19.99 per month, $199.99 per year or $299.99 for three years.
